Company overview
Ambry Genetics, a Tempus Company, specializes in clinical genetic testing using advanced genomic technologies like DNA/RNA analysis and next-generation sequencing (NGS) for hereditary cancers, oncology, neurology, and rare diseases. They offer pharma services supporting drug development across therapeutic areas including gene therapy and cardiovascular diseases, with a CLIA/CAP-certified SuperLab for high-volume and customized testing. Their expertise translates research into actionable insights for pharmaceutical partners and clinicians.
Ambry Genetics is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include genetic testing, genomic testing, pharma services, hereditary cancer, ngs sequencing, clia lab.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.ambrygen.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- genetic testing, genomic testing, pharma services, hereditary cancer, ngs sequencing, clia lab
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What pharma services does Ambry Genetics provide?
- Ambry supports drug development with genetic insights for oncology, neurology, cardiovascular diseases, gene therapy, gastroenterology, and rare diseases, using a CLIA/CAP-certified lab for customized research projects.
- What are Ambry's lab certifications and capabilities?
- Their 65,000 sq. ft. SuperLab is CLIA/CAP-certified, New York approved, and equipped for NGS, Sanger sequencing, biomarker development, and high-volume automated testing to ensure precision and efficiency.
- What therapeutic areas does Ambry cover?
- Key areas include oncology (e.g., pan-cancer panels like CancerNext-Expanded), neurology, cardiovascular diseases, gene therapy, gastroenterology, and rare diseases, with comprehensive hereditary cancer testing.
Related editorial coverage
- FDA Approves Companion Diagnostic for Inavolisib in HR+/HER2–, PIK3CA-Mutated Breast Cancer
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
